Clinical Trial

Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome

Study acronym: PRECISION
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The PRECISION is a proof-of-concept, phase II randomized clinical trial aiming to evaluate the efficacy and safety of anakinra in patients with Post-Acute COVID Syndrome (PACS) of the pro-inflammatory respiratory phenotype. Improvement is measured by a composite endpoint, namely, the "Score of PACS progression reversal"
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-06-28; most recent amendment 2026-01-06.
Status change: Not Yet Recruiting → Recruiting 2023-09-21
Trial Details
NCT Number NCT05926505
Lead Sponsor Hellenic Institute for the Study of Sepsis
Conditions Post-Acute COVID-19 Syndrome, Post-Acute COVID-19, Long COVID
Enrollment 182 participants
Start Date 2023-09-06
Primary Completion 2028-03 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-01-08